Krzysztof W Selmaj
Overview
Explore the profile of Krzysztof W Selmaj including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
3868
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Cwiklinska H, Cichalewska-Studzinska M, Selmaj K, Mycko M
Int J Mol Sci
. 2020 Apr;
21(8).
PMID: 32316658
T helper cells type 17 (Th17) are orchestrators of autoimmune conditions, including multiple sclerosis (MS), but mechanisms of Th17 pathogenicity remain unknown. MicroRNAs (miRNA) are known to control T cells....
12.
Cohen J, Comi G, Selmaj K, Bar-Or A, Arnold D, Steinman L, et al.
Lancet Neurol
. 2019 Sep;
18(11):1021-1033.
PMID: 31492652
Background: Ozanimod is a sphingosine 1-phosphate receptor modulator, which selectively binds to sphingosine 1-phosphate receptor subtypes 1 and 5 with high affinity. In the RADIANCE phase 2 study in participants...
13.
Comi G, Kappos L, Selmaj K, Bar-Or A, Arnold D, Steinman L, et al.
Lancet Neurol
. 2019 Sep;
18(11):1009-1020.
PMID: 31492651
Background: Ozanimod, a sphingosine 1-phosphate receptor modulator, selectively binds to receptor subtypes 1 and 5 with high affinity. The RADIANCE phase 2 study showed that ozanimod had better efficacy than...
14.
Zurawska A, Mycko M, Selmaj K
J Neuroimmunol
. 2019 Jun;
334:576971.
PMID: 31163273
Multiple sclerosis (MS) is believed to be an autoimmune disease of the central nervous system (CNS) in which autoreactive immune cells recognizing myelin antigens lead to demyelination and axonal injury....
15.
Cuker A, Bass A, Nadj C, Agius M, Steingo B, Selmaj K, et al.
Mult Scler
. 2019 Feb;
26(1):48-56.
PMID: 30785358
Background: Alemtuzumab is a highly effective therapy for relapsing-remitting multiple sclerosis (RRMS), and immune thrombocytopenia (ITP) has been identified as a risk. Objective: To examine ITP incidence, treatment, and outcomes...
16.
Wray S, Havrdova E, Snydman D, Arnold D, Cohen J, Coles A, et al.
Mult Scler
. 2018 Oct;
25(12):1605-1617.
PMID: 30289355
Background: Reduced MS disease activity with alemtuzumab versus subcutaneous interferon beta-1a (SC IFNB-1a) in core phase 2/3 studies was accompanied by increased incidence of infections that were mainly nonserious and...
17.
Cohen J, Comi G, Arnold D, Bar-Or A, Selmaj K, Steinman L, et al.
Mult Scler
. 2018 Jul;
25(9):1255-1262.
PMID: 30043658
Background: Ozanimod, an oral immunomodulator, selectively targets sphingosine 1-phosphate receptors 1 and 5. Objective: Evaluate efficacy, safety, and tolerability of ozanimod in relapsing multiple sclerosis. Methods: In the RADIANCE Part...
18.
Rose J, Giovannoni G, Wiendl H, Gold R, Havrdova E, Kappos L, et al.
Mult Scler Relat Disord
. 2017 Oct;
17:32-40.
PMID: 29055471
Background: Daclizumab beta is a humanized monoclonal antibody specific for the human interleukin-2 receptor alpha chain (CD25). In two pivotal studies in relapsing multiple sclerosis (MS), patients treated with daclizumab...
19.
Coles A, Cohen J, Fox E, Giovannoni G, Hartung H, Havrdova E, et al.
Neurology
. 2017 Aug;
89(11):1117-1126.
PMID: 28835403
Objective: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. Methods: In the 2-year Comparison of Alemtuzumab and...
20.
Havrdova E, Arnold D, Cohen J, Hartung H, Fox E, Giovannoni G, et al.
Neurology
. 2017 Aug;
89(11):1107-1116.
PMID: 28835401
Objective: To evaluate 5-year efficacy and safety of alemtuzumab in treatment-naive patients with active relapsing-remitting MS (RRMS) (CARE-MS I; NCT00530348). Methods: Alemtuzumab-treated patients received treatment courses at baseline and 12...